Time to go on offence with Canada’s bio-manufacturing strategy

To ensure we do not experience the same issues in the future around emerging technology platforms, we need to transition from a pandemic focus and execute on a robust manufacturing strategy that leverages Canadian strengths for meaningful benefit to Canada and measurable global leadership.

Stainless steel bioreactors, pictured. It is encouraging and exciting that bio-manufacturing has become a priority of the Canadian life sciences enterprise, and it is understandable that recent investments have been driven by COVID-19 vaccine development and manufacturing, writes Michael May. Photograph courtesy of Commons Wikimedia/Rick Lawless

Opinion

BY MICHAEL MAY

September 13, 2021

The COVID-19 pandemic is a health-care crisis. It has, in many ways, focused a lens on the importance of the life sciences, technology development, and innovation strategy on the health and economic well-being of all Canadians. Yet, we all ache for the COVID context to be finally removed from all ou...

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.

Already a Subscriber?

Get Weekend Point of View Newsletter

A round up of the past weekâ€™s opinion writers and columnists on Saturdays and Sundays.

By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy